Saisheng Pharmaceutical announced that its subsidiary Saierbio recently received a “Notice of Acceptance” from the State Drug Administration for the registration and marketing of dagliflozin tablets domestically produced and marketed. The specifications are 5 mg and 10 mg. Dapagliflozin is an SGLT-2 inhibitor that entered the Chinese market in 2017. The acceptance of the application means that the variety has entered the registration review stage, and there is no significant impact on recent performance. If it successfully passes the review, it will enrich the competition and biological product pipeline. Drug registration approval times and results are uncertain, reminding investors to be aware of the risks.

Saisheng Pharmaceutical announced that its subsidiary Saierbio recently received a “Notice of Acceptance” from the State Drug Administration for the registration and marketing of dagliflozin tablets domestically produced and marketed. The specifications are 5 mg and 10 mg. Dapagliflozin is an SGLT-2 inhibitor that entered the Chinese market in 2017. The acceptance of the application means that the variety has entered the registration review stage, and there is no significant impact on recent performance. If it successfully passes the review, it will enrich the competition and biological product pipeline. Drug registration approval times and results are uncertain, reminding investors to be aware of the risks.